Issue 3
-
Results from EMERALD trial and key findings from PI3K pathway inhibitor study presented at #SABCS21
Wednesday’s General Session featured new data about the oral SERD elacestrant and the effect of tamoxifen on uterine cancer risk.
-
McGuire Award Lecture: Moving to precision care in breast cancer
Olufunmilayo I. Olopade, MD, FAACR, recounted her lifelong journey through breast cancer genomics during the William L. McGuire Memorial Lecture on Wednesday.
-
Regulatory session covers latest breast cancer treatment approvals
A special session on Wednesday reviewed the Food and Drug Administration’s recent approval of pembrolizumab for neoadjuvant and adjuvant treatment, and abemaciclib in the adjuvant setting.
